Bianucci to sell Biofield's breast test in Italy:
This article was originally published in Clinica
Executive Summary
Atlanta, Georgia-based Biofield has appointed Bianucci di Bianucci as exclusive distributor of its Biofield diagnostic system (BDS) for the detection of breast cancer. The deal with the Lucca, Italy-based company is for three years. The product is used for a 15-minute noninvasive, office-based test, which helps to characterise the severity of a breast lesion and gives an immediate result. Bianucci says that Italy has one of highest rates of breast cancer in Europe.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.